Abstract 580P
Background
ARCHER 1050 has demonstrated a potential efficacy of first-line dacomitinib for Chinese non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 21L858R mutation but with limited data. This study aims to provide more evidence for the application of first-line dacomitinib treating advanced NSCLC patients with EGFR 21L858R mutation in China and explore influential factors of clinical outcomes.
Methods
A longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data was conducted. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included duration of treatment (DOT), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.
Results
A total of 155 EGFR 21L858R mutant patients treated with first-line dacomitinib were included into this study. The median follow-up time for these patients was 20.4 months. Among 134 patients with target lesions, the ORR was 70.9% and the DCR was 96.3%. The median PFS was 16.3 months (95%CI, 13.7-18.9). Univariate Cox regression analysis suggested that baseline brain metastasis (BM) status (with vs. without BM: HR, 1.171; 95%CI, 0.730-1.878; p = 0.513) and initial dose (45mg vs. 30mg: HR, 0.980; 95%CI, 0.564-1.701; p = 0.943) didn’t have significant impact on the median PFS. The median DOT was 21.0 months (95%CI, 17.5-24.6) and the median OS was not reached. The most common grade 3-4 adverse events were rash (10.4%), diarrhea (9.1%), stomatitis (7.1%) and paronychia (4.5%).
Conclusions
First-line dacomitinib treatment demonstrated promising efficacy and tolerable adverse events among Chinese NSCLC patients with EGFR 21L858R mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract